Practice of L-Asparaginase Usage: A Survey among Healthcare Providers Treating Children with Cancer in India

Author:

MV Archana1,VS Kalasekhar2ORCID,Munikoty Vinay1,Bhat Ramitha R.1,Achyutrao Atul1,Lakshmi R Vani3,Bhat K Vasudeva1ORCID

Affiliation:

1. Division of Pediatric Hematology and Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India.

2. Department of Pediatric Oncology, Regional Cancer Centre, Trivandrum, Kerala, India

3. Department of Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India

Abstract

Introduction L-asparaginase is an essential chemotherapeutic agent in the therapy of acute lymphoblastic leukemia (ALL), which has led to improvement in survival. In low- and middle-income countries like India, the outcomes in ALL are inferior compared with the published literature, one of the causes of which is believed to be due to the inferior quality of bioequivalent asparaginase. Objective The following survey attempts to understand the practice of using this agent among oncologists treating children with cancer in our country. Methods The researchers designed a structured online questionnaire comprising 25 aspects of L-asparaginase usage in the study. The questionnaire was directed to the healthcare providers involved in treating children with cancer in India. Results Of the total 80 responses recorded, 51 (64%) respondents had more than 5 years of experience in pediatric oncology and were treating at least 5 to 10 newly diagnosed ALL patients per month. Forty-one (51%) respondents utilized native asparaginase, and 21 (26.3%) oncologists used PEGylated-asparaginase exclusively. The most common route of administration was the intramuscular route (66.3%). Seventy percent of respondents utilized native form at a dose of 10,000 IU/m2 and 20% at 6,000 IU/m2. The amounts used for PEGylated L-asparaginase were 1,000,IU/m2, 2,500,IU/m2, and variable doses in 48, 40, and 10% of responses, respectively. Though serum asparaginase assay (SAA) was not measured routinely in most of the centers, 39 (48.8%) healthcare providers perceived performing SAA helps to make the clinical decision. Conclusion This survey shows a wide variation in L-asparaginase usage among healthcare providers caring for children with cancer in our country. As L-asparaginase is the pivotal component of ALL therapy, uniformity in its usage and dosing with the possibility of monitoring SAA due to the quality of bioequivalent may be one of the critical steps toward improving outcomes in ALL in our country.

Publisher

Georg Thieme Verlag KG

Subject

Cancer Research,Oncology

Reference20 articles.

1. Treatment of acute lymphoblastic leukemia;C H Pui;N Engl J Med,2006

2. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia;S E Sallan;Cancer Res,1983

3. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia;L A Clavell;N Engl J Med,1986

4. Comparative pharmacokinetic studies of three asparaginase preparations;B L Asselin;J Clin Oncol,1993

5. Asparaginase pharmacology: challenges still to be faced;C Lanvers-Kaminsky;Cancer Chemother Pharmacol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3